Search Tag: biotechnology
2023 12 Sep
Northwest Biotherapeutics, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announces that Dr. Linda Liau, MD, PhD, MBA has joined the Company’s Scientific Advisory Board (SAB). Dr. Liau served as the Principal Investigator of the Phase 3 trial of DCVax®-L for treatment of glioblastoma. She is Chair...Read more
2023 23 Jun
Heron Therapeutics, Inc., a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced the appointment of Ira Duarte as Chief Financial Officer. Ms. Duarte has more than twenty-five years of experience in a variety of...Read more
2022 30 Sep
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction announced that Robert Weiskopf, Stealth's chief financial officer, is leaving the company effective September 30, 2022. Mr. Weiskopf joined Stealth in 2019...Read more
2022 13 Sep
A seasoned executive with deep knowledge and experience of biotechnology and healthcare operations. Vyriad, Inc., a biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, announces the appointment of Scott Beck, MBA as Chief Operating Officer. During the past three decades Mr. Beck held many leadership...Read more
2022 06 Sep
Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics announced the appointment of Richard L. Schilsky, MD, FASCO, FACP, FSCT to its Board of Directors, effective September 1, 2022. Dr. Schilsky brings over 40 years of experience in medicine and clinical research, specializing in new drug...Read more
2022 13 Apr
Longtime clinical development leader will help advance pipeline of precision medicines for genetically defined neurological and immunological diseases, with initial focus on Parkinson’s disease Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological...Read more
2022 02 Mar
OncoMyx Therapeutics, a privately-held oncolytic virus immunotherapy company has announced the appointment of Robert Williamson as Chief Business and Chief Financial Officer. Mr. Williamson has more than two decades of experience in building, financing, and leading private and public biotechnology companies through critical phases of growth. At OncoMyx,...Read more
2020 28 Oct
Speakers NVBL Co-Leads Michelle Buchanan, Oak Ridge National Laboratory, and Stephen Streiffer, Argonne National Laboratory Bruce Tromberg, Director, National Institute of Biomedical Imaging & Bioengineering, National Institutes of Health Jim Brase, Deputy Associate Director for Computation, Lawrence Livermore National Laboratory...Read more
2020 08 Jun
NOW A VIRTUAL EVENT DUE TO COVID-19 HEALTH CONCERNS Find Bio International Convention on Social Media Read more
2015 24 Sep
Hill-Rom Holdings, Inc.(NYSE: HRC ) announced the appointment of Dr.Dirk Ehlers as President, Trumpf Medical. Before joining Hill-Rom, Ehlers, 54, was President and Chief Executive Officer of Eppendorf, a life science tools company, based in Germany. Prior to Eppendorf, Ehlers served as the Head of Professional Diagnostics with Roche Diagnostics,...Read more
2014 13 May
Patent expiry, together with an increase in generic competition in the global pharmaceutical and biotechnology industry, is expected to bring a number of deals. According to newly released analysis from Frost & Sullivan entitled “Merger and Acquisition (M&A) Trends in the Global Pharmaceutical and Biotechnology Industry”, evolving conditions...Read more